StockNews.com Begins Coverage on Accelerate Diagnostics (NASDAQ:AXDX)

StockNews.com began coverage on shares of Accelerate Diagnostics (NASDAQ:AXDXFree Report) in a research report report published on Wednesday. The brokerage issued a hold rating on the medical research company’s stock.

Accelerate Diagnostics Stock Up 5.2 %

AXDX stock opened at $1.01 on Wednesday. Accelerate Diagnostics has a twelve month low of $0.83 and a twelve month high of $11.90. The company has a market cap of $14.72 million, a PE ratio of -0.19 and a beta of 0.51. The business’s 50-day simple moving average is $1.13 and its 200 day simple moving average is $3.74.

Institutional Investors Weigh In On Accelerate Diagnostics

Institutional investors have recently added to or reduced their stakes in the company. Sonora Investment Management Group LLC acquired a new stake in Accelerate Diagnostics during the third quarter worth about $63,000. Tejara Capital Ltd acquired a new stake in Accelerate Diagnostics during the third quarter valued at approximately $78,000. Bank of Montreal Can acquired a new stake in Accelerate Diagnostics during the first quarter valued at approximately $27,000. Cubist Systematic Strategies LLC acquired a new stake in Accelerate Diagnostics during the third quarter valued at approximately $29,000. Finally, Virtu Financial LLC boosted its holdings in Accelerate Diagnostics by 95.4% during the fourth quarter. Virtu Financial LLC now owns 35,771 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 17,461 shares in the last quarter. 17.14% of the stock is owned by institutional investors and hedge funds.

About Accelerate Diagnostics

(Get Free Report)

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.

See Also

Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.